Recent high-throughput sequencing approaches have identified IDH (IDH1 and IDH2), CIC, FUBP1 and TERT promoter mutations in oligodendroglioma (75, 50, 10 and 75%, respectively)2, 4, 5, IDH mutation status typically being associated with a better clinical outcome6. Here, IDH2 is linked to oligodendroglioma.